Key Points
- Nasus Pharma CEO Dan Benjamin Teleman bought 6,550 shares of the company at an average price of $3.10 per share, increasing his direct stake by 4.17% to 163,541 shares.
- The purchase was disclosed in an SEC filing and followed an earlier insider buy in April, when Teleman acquired 2,900 shares at $3.76 each.
- Shares of NSRX were up 1.6% to $3.12, while analysts currently have a consensus Buy rating with an average target price of $18.00, though Citizens JMP recently trimmed its target from $19 to $18.
Nasus Pharma Ltd. (NYSEAMERICAN:NSRX - Get Free Report) CEO Dan Benjamin Teleman purchased 6,550 shares of the company's stock in a transaction on Wednesday, June 17th. The shares were bought at an average cost of $3.10 per share, with a total value of $20,305.00. Following the transaction, the chief executive officer directly owned 163,541 shares of the company's stock, valued at $506,977.10. This represents a 4.17% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.
Dan Benjamin Teleman also recently made the following trade(s):
- On Wednesday, April 22nd, Dan Benjamin Teleman purchased 2,900 shares of Nasus Pharma stock. The stock was bought at an average cost of $3.76 per share, with a total value of $10,904.00.
Nasus Pharma Trading Up 1.6%
Shares of NYSEAMERICAN:NSRX opened at $3.12 on Tuesday. Nasus Pharma Ltd. has a 52-week low of $1.98 and a 52-week high of $9.99. The firm has a fifty day moving average of $2.96.
Wall Street Analyst Weigh In
Separately, Citizens Jmp reduced their target price on shares of Nasus Pharma from $19.00 to $18.00 and set a "market outperform" rating on the stock in a report on Thursday, March 26th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $18.00.
View Our Latest Stock Analysis on NSRX
About Nasus Pharma
(
Get Free Report)
Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions. Nasus Pharma Ltd. is based in TEL AVIV, Israel.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
